LSB

LakeShore Biopharma Co., Ltd · NASDAQ

Sector Health Technology
Industry Biotechnology
Website ysbiopharm.com
Employees(FY) 773
ISIN KYG9845F2080

Performance

+23.33%

+1.83%

-57.21%

-45.63%

-34.83%

YTD

-27.61%

Profile

LakeShore Biopharma Co., Ltd, a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was formerly known as YS Biopharma Co., Ltd. and changed its name to LakeShore Biopharma Co., Ltd in May 2024. LakeShore Biopharma Co., Ltd was founded in 2002 and is based in Beijing, China.

Advanced Technical Analysis

Technical Analysis of LSB 2024-12-27

The Moving Average Score of 63 indicates a bullish sentiment, while the Oscillators Score of 40 suggests a neutral stance, and the overall Technical Score of 51 reinforces a mixed outlook. This combination implies that while there is some bullish momentum, caution is warranted due to the neutral oscillator readings.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of LSB

Stock Rank

Recent News & Updates

2024-12-18 20:05
LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance(Prnewswire)
2024-12-12 06:57
LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in China(Yahoo Finance)
2024-11-06 19:00
LakeShore Biopharma Initiates Biologics License Application of PIKA Rabies Vaccine to the Drug Regulatory Authority of Pakistan(Globenewswire)
2024-10-28 20:30
LakeShore Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement(Prnewswire)
2024-10-25 21:00
LakeShore Biopharma Advances with Rabies Vaccine Trial(Yahoo Finance)
2024-10-24 20:30
LakeShore Biopharma Granted Phase III Clinical Trial Approval to Explore Simplified Regimens for YSJA Rabies Vaccine(Prnewswire)
2024-10-07 20:30
LakeShore Biopharma Provides Fiscal Half Year 2025 Financial Guidance and Reaffirms Fiscal Year 2025 Financial Guidance(Prnewswire)
2024-09-26 19:00
LakeShore Biopharma Announces Results of Extraordinary General Meeting on Share Consolidation(Prnewswire)
2024-09-09 20:00
Lakeshore Biopharma to Hold an Extraordinary General Meeting of Shareholders on September 27, 2024(Prnewswire)
2024-09-03 20:00
LakeShore Biopharma Announces Leadership Transitions(Prnewswire)
2024-08-14 20:30
LakeShore Biopharma Announces Financial Results for Fiscal Year 2024(Prnewswire)
2024-07-04 19:00
LakeShore Biopharma to Hold an Extraordinary General Meeting on July 25, 2024, Pursuant to Shareholders' Requisition(Prnewswire)
2024-05-23 19:30
YS Biopharma Announces Name Change to LakeShore Biopharma(Prnewswire)
2024-05-21 04:15
YS Biopharma Announces Results of Extraordinary General Meeting(Prnewswire)
2024-05-07 04:20
YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer(Prnewswire)
2024-04-28 20:00
YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule(Prnewswire)
2024-04-21 21:10
YS Biopharma Co., Ltd. (NASDAQ:YS) Q3 2024 Earnings Call Transcript(Insidermonkey)
2024-04-18 23:52
YS Stock Earnings: YS Biopharma Co Misses EPS, Beats Revenue for Q3 2024(Investorplace)
2024-04-18 19:00
YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024(Prnewswire)
2024-04-17 20:00
YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine(Prnewswire)
2024-04-15 20:00
YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024(Prnewswire)
2024-04-08 22:06
YS Biopharma's rabies vaccine bests approved competitor in interim phase 3 readout(Fiercebiotech)
2024-04-08 20:00
YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine(Prnewswire)
2024-04-02 20:00
YS Biopharma Announces Full Repayment of US$40,000,000 Loan Facility(Prnewswire)
2024-03-04 19:00
YS Biopharma Announces Board Changes and Strategic Leadership Appointments in Chinese Subsidiaries(Prnewswire)
2024-02-22 04:00
YS Biopharma Announces Results of Extraordinary General Meeting held on February 22, 2024(Prnewswire)
2024-02-17 15:30
/C O R R E C T I O N -- YS Biopharma Co., Ltd./(Yahoo Finance)
2024-02-16 07:20
YS Biopharma Announces Results of Extraordinary General Meeting and Responds to False Statements about the Meeting(Prnewswire)
2024-02-16 04:36
Shareholders Led by Yi Zhang Announce Successful Results of Removal of Directors and Election of New Directors of YS Biopharma Co., Ltd.(Prnewswire)
2024-02-13 19:00
YS Biopharma to Hold an Extraordinary General Meeting on February 22, 2024 pursuant to a Shareholder Requisition to Enhance Corporate Governance(Prnewswire)

Page 1 of 3

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.